---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-25-000127"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:48:13.835895+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Exelixis Q3 revenues $597.8M, EPS $0.69; announces $750M stock buyback by 2026

## Summary
- Total revenues $597.8M (+10.8% YoY); cabozantinib US net product rev $542.9M (+13.5% YoY).
- GAAP diluted EPS $0.69 (vs $0.40); Non-GAAP diluted EPS $0.78 (vs $0.47).
- Board authorized $750M stock repurchase program through Dec 31, 2026.
- Restructuring charges $19.8M related to corporate reorganization; plan to close King of Prussia office.
- Zanzalintinib NDA submission planned before year-end based on positive STELLAR-303 colorectal cancer data.

## SEC filing metadata
- accession: 0000939767-25-000127
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976725000127/0000939767-25-000127-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976725000127/exel-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-25-000127
- JSON: https://secwatch.observer/filing/0000939767-25-000127.json
- Plain text: https://secwatch.observer/filing/0000939767-25-000127.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.